Some recent studies have demonstrated that the fusion is a clinically useful prognostic biomarker for MEC, and the highest incidence of the CRTC1-MAML2 fusion is found in low- and intermediate-grade MEC with favorable prognosis [7–9]. The gene discussed is CRTC1; the disease is mucoepidermoid carcinoma.